WSLCB Director Rick Garza spoke about restructuring agency enforcement and the Committee heard HB 2296 and HB 2300 regarding cannabidiol (CBD) products.
Public hearings on cannabis-related bills HB 2263 and HB 2361 filled the hearing room to capacity, and generated significantly more resistance than promotion.
Board members received training from the Executive Ethics Board and discussed the addition of a second patient representative to the Cannabis Advisory Council.
New details on the WSLCB’s legislative agenda, a Regulators Roundtable redux, plus an update on testing labs, the traceability contract, and the Hillard Heintze report.
SBOH's legal counsel briefed on progress of a lawsuit against the agency over their authority to enact an emergency ban on flavored vapor products.
The Board reviewed the latest information on vapor associated lung injuries (VALI).
The Board was treated to a sweeping survey of the agency’s prevention and public health efforts before a swift public hearing on the Cannabis Penalties rulemaking project.
Attendees introduced themselves, indicating a mix of prevention, public health, and industry perspectives would be shared on the topic of packaging and labeling (PAL).